Ventures

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.

AGO have developed a handy tool called the Aortic Root Pressurizing Device (ARPD) to help during heart surgeries. This device allows surgeons to check the success of aortic valve repairs while the heart is temporarily stopped. It helps avoid the need to restart the heart to check, which can be risky and time-consuming. The ARPD makes surgeries safer, quicker, and cheaper by allowing surgeons to verify their work during the operation. It's easy to use and disposable, so it doesn't add much hassle to the surgery process.

Haermonics addresses the challenge of complications after open heart surgery with a transformative solution. Excessive blood loss and clots post-surgery lead to numerous issues, including reoperations and cardiac tamponades, resulting in significant healthcare costs and loss of lives. The Haermonics Flush device offers a preventive approach by flushing the pericardial cavity after surgery, limiting blood loss and clot formation. By providing medical professionals with better patient status monitoring, Haermonics Flush empowers doctors to make more informed decisions, ultimately saving thousands of lives and billions in hospital costs.

Timelab addresses the challenge of ambulance delays in the Netherlands by offering a proactive solution through their Emergency Mathematics software. With 7% of ambulance arrivals exceeding the 15-minute target, 35,000 patients annually don't receive timely care, impacting mortality and morbidity rates. Timelab's software predicts future demand and facilitates the proactive relocation of ambulances, aiming to reach 95% of high emergency call locations within 15 minutes, compared to the current 93%.

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

AIDO enhances precision control during endoscopic procedures with its drive unit. Physicians can now maintain control of the endoscope shaft while operating tools, saving time and improving efficiency. This platform technology streamlines the control of instruments inserted through the endoscope's working channel, offering automatic insertion and precise control, ultimately improving patient safety and procedural outcomes.

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.